Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. Wunderink RG, et al. Among authors: dudley mn. Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1. Infect Dis Ther. 2018. PMID: 30270406 Free PMC article.
Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.
Alexander EL, Loutit J, Tumbarello M, Wunderink R, Felton T, Daikos G, Fusaro K, White D, Zhang S, Dudley MN. Alexander EL, et al. Among authors: dudley mn. Open Forum Infect Dis. 2017 Jun 1;4(2):ofx063. doi: 10.1093/ofid/ofx063. eCollection 2017 Spring. Open Forum Infect Dis. 2017. PMID: 28584849 Free PMC article.
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ. Kaye KS, et al. Among authors: dudley mn. JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438. JAMA. 2018. PMID: 29486041 Free PMC article. Clinical Trial.
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.
Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. Sabet M, et al. Among authors: dudley mn. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01969-17. doi: 10.1128/AAC.01969-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29133570 Free PMC article.
Potency of Meropenem-Vaborbactam in Lung Surfactant.
Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O. Rubio-Aparicio D, et al. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01702-17. doi: 10.1128/AAC.01702-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29038266 Free PMC article.
149 results